SSY Group Receives Approval for Levamlodipine Besilate Tablets to Treat Hypertension in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Approval Announcement: SSY Group Limited has received approvals from China's National Medical Products Administration for Levamlodipine Besilate Tablets (5mg and 2.5mg), classified as type 4 chemical drugs.
Therapeutic Use: The tablets are indicated for treating hypertension, providing options for both standalone and combination therapy to effectively manage elevated blood pressure and reduce cardiovascular risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
